United States: Capitol Hill Healthcare Update - September 25, 2017

GOP Divisions Threaten to Sink ACA Repeal Effort – Again

Republicans' last-ditch effort to overhaul the Affordable Care Act (ACA) suffered potentially fatal blows as GOP senators in recent days voiced either outright opposition to or serious reservations about legislation pushed by Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.).

The senators' bill would repeal the ACA's individual and employer mandate penalties and turn the law's Medicaid expansion into a trillion-dollar block grant to states. Graham and Cassidy also were readying last-minute funding and regulatory changes in an effort to woo reluctant Republican colleagues in advance of today's Senate Finance Committee hearing on the legislation.

Republicans plan to begin Senate floor debate on the bill Wednesday with a key procedural vote. It is not clear whether today's changes to Graham-Cassidy are sufficient to win over at least 50 Republicans for that test vote and later to pass the bill. Without a clear path forward, Senate Majority Leader McConnell has said he does not want his party to go through an excruciating exercise like July's one-vote failure to advance a different version of ACA replace legislation.

To date there have been no indications even one Democrat – such as Sen. Joe Manchin (D-W.V.) – would break with their party and back Graham-Cassidy. Republicans hold 52 Senate seats, so if more than two GOP senators defect, the legislation would fail.

Sen. Rand Paul (R-Ky.) earlier said he could not support Graham-Cassidy because it keeps most of the ACA's spending and taxes in place even as it shifts decision-making to the states. Because those block grants are at the heart of Graham-Cassidy, it is doubtful legislative accommodations could be made to win Paul's support. Still, Senate leaders and the White House were hopeful to persuade Paul with other provisions.

Sen. John McCain (R-Ariz.) on Friday announced his opposition to the bill, despite the strong backing of Arizona's Republican governor and McCain's long-standing friendship with Graham. McCain's no vote brought down Republicans' last effort to overhaul the ACA in July.

Sen. Susan Collins (R-Maine) has expressed "strong reservations" about Graham-Cassidy, including its redistribution of Medicaid funding from states that expanded their programs under the ACA as well as blocking Planned Parenthood from receiving federal reimbursements. Collins has not definitively said she is voting against the bill, but most GOP leadership staff believe she will not support it.

Sen. Lisa Murkowski (R-Alaska) also said she is concerned about Medicaid and Planned Parenthood. Alaska's independent governor has come out against Graham-Cassidy. Like Collins, Murkowski has not yet said how she would vote.

Complicating an already daunting task for Republican leaders, Sen. Ted Cruz (R-Texas) said Sunday he could not support the bill in its current form – despite Texas seeing a significant increase in Medicaid spending and regulatory flexibility under Graham-Cassidy. Some Senate Republicans believe Cruz is withholding his vote in order to gain concessions but that he would ultimately support the bill.

Republicans face a Saturday deadline to use the fast-track reconciliation procedures that allow them to pass the legislation on a party-line vote. After September 30, Republicans would need 60 votes to block a Democrat filibuster.

Do Republicans Turn Back to ACA Stabilization Efforts?

Senate HELP Committee Chairman Lamar Alexander (R-Tenn.) last week stopped bipartisan talks on shoring up the ACA's individual markets, while Republican leaders focused on a final effort to repeal the ACA.

But with ACA overhaul legislation backed by Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.) possibly dead, Alexander is expected to try to revive efforts with top committee Democrat Patty Murray (D-Wash.). The senators had been working on ways to stabilize insurance premiums in the ACA's individual markets.

The outlines of the agreement would extend the healthcare law's cost-sharing reduction payments to insurers to subsidize coverage premiums for individuals while also providing states with increased flexibility to approve low-cost insurance plans.

Those waiver details, however, have not been settled and likely represent the biggest threat to an agreement. Republicans want to give states broad flexibility to bring down rates mostly by relaxing coverage requirements, but Democrats warn they will not back waivers that undermine the ACA's consumer protections and coverage mandates.

House Republicans Seek Answers From Merck on Cyber Attack

Leaders on the House Energy and Commerce Committee last week sought information from Merck and the U.S. Department of Health & Human Services (HHS) on a malware attack that struck the company last summer and continues to affect its drug supply.

Energy and Commerce Committee Chairman Greg Walden (R-Ore.) and Rep. Tim Murphy (R-Pa.), the panel's Oversight and Investigations Subcommittee chairman, wrote letters to Merck CEO Ken Frazier and HHS Secretary Tom Price.

While the Merck malware attack has been known about for several months, the company only recently said the attack continues to affect its operations. Walden and Murphy said they wanted to understand more about the event and its ongoing consequences to determine whether the committee should consider a legislative response to protect the healthcare sector from future cyber threats.

Although only Republicans signed the letters, the committee did conduct a bipartisan inquiry last year into cyber vulnerabilities for medical devices, particularly devices connected to the Internet.

Meanwhile, on Wednesday the House Oversight and Government Reform Committee will hold a hearing on cyber threats to the Internet of Things. Witnesses are expected to discuss cyber risks for medical devices.

Medicare 'Extenders' to Be Added to FAA, Flood Bill

Several Medicare programs scheduled to expire this month are expected to be included in House legislation introduced this week that would reauthorize separate transportation and flood insurance programs.

The Medicare "extenders" include an intravenous immune globulin pilot project, a teaching health center graduate medical education program and a diabetes program for Native Americans. Those programs would be added to legislation renewing the Federal Aviation Administration through next spring.

The intravenous immune globulin pilot project, which would be reauthorized through 2020, treats individuals with lupus and weakened immune systems. Under the $45 million project, Medicare covers services to administer intravenous immune globulin to up to 4,000 patients in their homes.

To offset costs for the programs, the bill would cut $50 million from the Medicare Improvement Fund's $270 million budget beginning in fiscal 2021. That fund aims to facilitate improvements to Medicare hospital coverage under Part A and physicians' services under Part B.

Senior HHS Officials to Testify at Senate Opioid Hearing

Four top HHS officials will testify next week during a Senate HELP Committee hearing about the federal government's response to the opioid crisis.

The committee also will review implementation of last year's Comprehensive Addiction and Recovery Act, which authorizes $181 million to support opioid prevention and treatment programs. The panel will discuss implementation of the 21st Century Cures Act, which included $1 billion in grants to states to combat opioid abuse.

Scheduled witnesses at the October 5 hearing include Food and Drug Administration (FDA) Commissioner Scott Gottlieb, National Institutes of Health (NIH) Director Francis Collins, Centers for Disease Control and Prevention (CDC) Director Brenda Fitzgerald and Elinore McCance-Katz, an assistant secretary at the Substance Abuse and Mental Health Services Administration.

Hatch Calls on CMS to Slow Changes to Home Healthcare

The chairman of the Senate Finance Committee last week said the Centers for Medicare & Medicaid Services (CMS) should exercise "more robust data analysis" when updating a proposed rule that would change how and when Medicare reimburses for home health services.

In a letter to CMS Administrator Seema Verma, Sen. Orrin Hatch (R-Utah) said "CMS may be rushing to finalize complex policy changes too quickly" in the 2018 Home Health Prospective Payment System proposed rule.

CMS proposed new payment models and other changes that differed from recent Medicare Payment Advisory Commission recommendations. Hatch called on Verma to "refrain from finalizing" the proposed rule and to provide stakeholders time to fully analyze potential changes and provide substantive input.

Panel May Hold Hearing on 'Right-To-Try' Legislation

The House Energy and Commerce Health Subcommittee may hold a hearing next week on legislation that would give terminally-ill patients wider access to prescription drugs that haven't yet won FDA approval.

It is not clear whether the subcommittee would hold a hearing on House legislation introduced earlier this year by Rep. Andy Biggs (R-Ariz.) or legislation by Sen. Ron Johnson (R-Wis.) that won Senate approval last month. Johnson's bill would apply only to prescription drugs; the House bill would apply to drugs and medical devices.

Vice President Pence earlier this year endorsed the right-to-try legislation. Pharmaceutical manufacturers have resisted the legislation, saying early access to unapproved drugs could give patients false hope and threaten the integrity of ongoing clinical trials if those patients have adverse reactions.

Grassley: CMS Should Make Hospital Inspection Reports Public

The chairman of the Senate Judiciary Committee is calling on a CMS accrediting agency to publicly release hospital inspection reports.

In a letter to CMS's Administrator Seema Verma, Sen. Chuck Grassley (R-Iowa) wrote that making reports public would help patients decide where to seek care.

Grassley said the Joint Commission also appears to be failing to hold accountable facilities that have not properly cared for patients. He said there are more than 30 instances of hospitals retaining full accreditation even as CMS deemed their violations to be so significant they caused or were likely to cause a risk of serious injury or death to patients.

The senator asked CMS to respond to a series of questions about the inspections reports by October 3.

Lawmakers Question Price's Use of Private Jets

Following news reports that HHS spent more than $400,000 on private jet travel in recent months for Secretary Tom Price, House Democrats are calling for congressional oversight hearings.

HHS announced it would halt Price's private travel while reviews – including by HHS's inspector general – are underway. The department did not explain why the secretary needed to use private jets for 24 trips since early May, according to media reports.

Rep. Elijah Cummings (D-Md.), the top Democrat on the House Oversight and Government Reform Committee, called on panel leaders to examine Price's use of private travel for official business.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.